EcoDrugPlus

Nuclear Factor Erythroid 2-Related Factor 2-Like

Ensembl ID : ENSOTSG00005030391
Gene Symbol: LOC112254044
3 Cross references
199 Possible Orthologues:

Nuclear Factor Erythroid 2-Related Factor 2-Like

Ensembl ID : ENSOTSG00005018904
Gene Symbol: LOC112219800
3 Cross references
199 Possible Orthologues:

Nuclear Factor Erythroid 2-Related Factor 2-Like

Ensembl ID : ENSOTSG00005018824
Gene Symbol: LOC112236958
3 Cross references
199 Possible Orthologues:

Nuclear Factor Erythroid 2-Related Factor 2-Like

Ensembl ID : ENSOTSG00005022553
Gene Symbol: LOC112220178
3 Cross references
199 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSOTSG00005003590
Gene Symbol: NFKB1
1 Cross references
194 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSOTSG00005046058
Gene Symbol: NR1H3
1 Cross references
384 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 4

Ensembl ID : ENSOTSG00005008684
Gene Symbol: NR1H4
1 Cross references
381 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 4

Ensembl ID : ENSOTSG00005037348
Gene Symbol: NR1H4
1 Cross references
381 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSOTSG00005047485
Gene Symbol: NR3C1
1 Cross references
198 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSOTSG00005003629
Gene Symbol: NR3C1
1 Cross references
198 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSOTSG00005033628
Gene Symbol: NR3C1
1 Cross references
198 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSOTSG00005007431
Gene Symbol: NR3C1
1 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).